UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate‐to‐severe psoriasis in five European countries

Journal of the European Academy of Dermatology and Venereology, 2017-08, Vol.31 (8), p.1316-1323

2017

Volltextzugriff (PDF)

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey

British journal of dermatology (1951), 2018-07, Vol.179 (1), p.173-181

2018

Volltextzugriff (PDF)

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Annals of oncology, 2016-10, Vol.27 (10), p.1940-1946

2016

Volltextzugriff (PDF)

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1033-1042

2017

Volltextzugriff (PDF)

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany

Journal of the European Academy of Dermatology and Venereology, 2018-12, Vol.32 (12), p.2191-2199

2018

Volltextzugriff (PDF)

Patient–dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real‐world multinational survey

Journal of the European Academy of Dermatology and Venereology, 2018-09, Vol.32 (9), p.1523-1529

2018

Volltextzugriff (PDF)

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Journal of the European Academy of Dermatology and Venereology, 2018-12, Vol.32 (12), p.2178-2184

2018

Volltextzugriff (PDF)

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

British journal of dermatology (1951), 2018-06, Vol.178 (6), p.1297-1307

2018

Volltextzugriff (PDF)

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Journal of the European Academy of Dermatology and Venereology, 2017-10, Vol.31 (10), p.1693-1699

2017

Volltextzugriff (PDF)

1222 Long-term clinical experiences of patients (pts) with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or metastatic melanoma (MEL): A SEER-Medicare analysis

European journal of cancer (1990), 2015-09, Vol.51, p.S179-S179

2015

Volltextzugriff (PDF)

3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO)

European journal of cancer (1990), 2015-09, Vol.51, p.S674-S675

2015

Volltextzugriff (PDF)

AB1359 Systematic literature review of publications on indirect comparisons for biologic agents in RA

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.715-715

2013

Volltextzugriff (PDF)

Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe

Value in health, 2013-11, Vol.16 (7), p.A403-A403

2013

Volltextzugriff (PDF)

Rates, Timing, and Costs of Short-Term Disability (Std) and Long-Term Disability (Ltd) in Patients With Newly Diagnosed Advanced Melanoma

Value in health, 2015-05, Vol.18 (3), p.A199-A199

2015

Volltextzugriff (PDF)

The Relative Clinical and Economic Value of Ipilimumab as First-Line Treatment of Metastatic Melanoma Versus Other Anti-Cancer Agents for Metastatic Diseases

Value in health, 2014-05, Vol.17 (3), p.A70-A70

2014

Volltextzugriff (PDF)

PCN63 The Relative Value of Dasatinib Versus Imatinib as First-Line Treatment for Chronic Myeloid Leukemia

Value in health, 2012-11, Vol.15 (7), p.A420-A420

2012

Volltextzugriff (PDF)

Psoriasis: clinical and epidemiological features and therapy issues

Vestnik dermatologij i venerologij, 2018-08, Vol.94 (3), p.67-76

2018

Volltextzugriff (PDF)

PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)

Value in health, 2012-06, Vol.15 (4), p.A105-A105

2012

Volltextzugriff (PDF)

PCN189 The Use of Parametric Survival Analysis to Predict Progression Free and Overall Survival of Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients

Value in health, 2011, Vol.14 (7), p.A469-A469

2011

Volltextzugriff (PDF)

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

Haematologica (Roma), 2014-03, Vol.99 (3), p.437-447

2014

Volltextzugriff (PDF)

PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE

Value in health, 2019-11, Vol.22, p.S421-S421

2019

Volltextzugriff (PDF)

PMS29 Abatacept or Infliximab for Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Trial-Based and Real-Life Cost-Consequence Analysis

Value in health, 2011, Vol.14 (7), p.A307-A307

2011

Volltextzugriff (PDF)

PSS31 - COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

Value in health, 2018-10, Vol.21, p.S428-S428

2018

Volltextzugriff (PDF)

PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

Value in health, 2018-10, Vol.21, p.S428-S428

2018

Volltextzugriff (PDF)

Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials

Acta dermato-venereologica, 2019-07, Vol.99 (9), p.820-821

2019

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(92)

Publikationsform

Artikel
(101)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(24)
Psoriasis
(24)
Dermatology
(21)
Quality Of Life
(18)
Adult
(17)
Female
(16)
Internal Medicine
(16)
Male
(16)
Middle Aged
(16)
Patients
(12)
Psoriasis - Drug Therapy
(12)
Productivity
(10)
Monoclonal Antibodies
(9)
Severity Of Illness Index
(9)
Absenteeism
(7)
Aged
(7)
Dermatologic Agents - Therapeutic Use
(7)
Severity
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate‐to‐severe psoriasis in five European countries

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany

Patient–dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real‐world multinational survey

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

1222 Long-term clinical experiences of patients (pts) with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or metastatic melanoma (MEL): A SEER-Medicare analysis

3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO)

AB1359 Systematic literature review of publications on indirect comparisons for biologic agents in RA

Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe

Rates, Timing, and Costs of Short-Term Disability (Std) and Long-Term Disability (Ltd) in Patients With Newly Diagnosed Advanced Melanoma

The Relative Clinical and Economic Value of Ipilimumab as First-Line Treatment of Metastatic Melanoma Versus Other Anti-Cancer Agents for Metastatic Diseases

PCN63 The Relative Value of Dasatinib Versus Imatinib as First-Line Treatment for Chronic Myeloid Leukemia

Psoriasis: clinical and epidemiological features and therapy issues

PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)

PCN189 The Use of Parametric Survival Analysis to Predict Progression Free and Overall Survival of Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE

PMS29 Abatacept or Infliximab for Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Trial-Based and Real-Life Cost-Consequence Analysis

PSS31 - COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials

Suchergebnisse filtern